Accreditation, governance, and expert oversight

Our medical cannabis education programme has been developed to support safe, responsible, and evidence-based clinical practice in a rapidly evolving area of medicine. It’s designed for healthcare professionals and clinical stakeholders who require clear and current information to guide clinical decision-making.

Each module is authored and reviewed by experienced clinicians and international subject matter experts. Content is informed by peer-reviewed research, established clinical guidance, and direct experience within regulated medical cannabis services.

Our commitment to clinical credibility

We’re on a mission to shape the future of research-driven cannabis education.

Curaleaf Education’s course reflects that commitment through:

  • Content grounded in published research and established clinical frameworks
  • Clear referencing of evidence, with transparent acknowledgement of areas of uncertainty
  • Practical guidance aligned with regulatory and prescribing requirements
  • Declared authorship and structured peer review

All materials are developed within a formal governance framework designed to ensure accuracy, balance, and professional integrity.

Governance and quality assurance

Robust clinical governance and clearly defined quality assurance processes underpin our medical cannabis course. These systems ensure that all content remains accurate and professionally rigorous.

Clinical oversight

The programme is overseen by the Curaleaf Education Panel, led by senior medical leadership. All content undergoes structured clinical review before publication and is reassessed at defined intervals to ensure continued relevance and compliance.

This includes:

  • Review against current evidence and regulatory standards
  • Verification of clinical claims, safety information, and risk communication
  • Confirmation of alignment with local prescribing frameworks
  • Documented version control, update cycles, and audit trails

Editorial standards

We prioritise clarity and professional neutrality. All of our educational materials:

  • Avoid promotional language
  • Distinguish clearly between evidence, consensus, and emerging data
  • Present benefits, risks, and limitations in a balanced way
  • Support independent clinical judgement

This approach reflects Curaleaf Education’s broader commitment to research and innovation.

United Kingdom

Dr Simon Erridge – Lead Author, Curaleaf International

Dr Simon Erridge is Research Director at Curaleaf Clinic, UK, and an academic clinician experienced in embedding evidence-based research into his practice. He has published over 100 peer-reviewed publications, including those from his PhD examining the effects of medical cannabis on chronic pain.

As Lead Author, Dr Erridge has shaped the educational framework and evidence synthesis underpinning the clinical content of the course.

Dr Mikael Sodergren – Chief Medical Officer, Curaleaf International, Head of Curaleaf Educational Panel

Dr Mikael Sodergren is Chief Medical Officer at Curaleaf International and a Clinical Associate Professor of Surgery and Technological Innovation. In his roles, he has established a bench-to-bedside research programme to evaluate and develop novel medicines derived from cannabis.

As Head of the Educational Panel, he provides senior clinical input and oversight to support the scientific integrity and quality of the course.

A UK-based multidisciplinary team

This course has been created and reviewed with input from members of the multidisciplinary clinical team at Curaleaf Clinic in the UK.

Curaleaf Clinic was the first medical cannabis clinic in the UK to be approved and regulated by the Care Quality Commission (CQC). Clinical practice aligns with guidance from the General Medical Council (GMC), the Medicines and Healthcare products Regulatory Agency (MHRA), and NHS England. Care delivery is informed by ongoing appraisal of emerging research and evolving regulatory standards.

UK clinical contributors include specialists across a range of disciplines:

  • Dr Michael Platt – Specialist in Chronic Pain
  • Dr James Rucker – Specialist in Psychiatric Conditions
  • Dr Shaheen Khan – Specialist in Palliative Care
  • Dr Mark Weatherall – Specialist in Neurological Conditions
  • Dr Sushil Beri – Specialist in Paediatric Neurology

Clinical insight from this multidisciplinary team informs the practical elements of the course, ensuring that content reflects real-world UK prescribing standards, governance requirements, and patient safety considerations.

Sweden

Dr Diana Kadetoff – Pain Specialist and Head of Research and Development, Sapphire Clinics Sweden

Dr Diana Kadetoff is a senior physician with extensive experience in multidisciplinary chronic pain management. She previously served as senior physician and unit manager at Capio Spine Center Stockholm and completed her doctoral research on fibromyalgia at Karolinska Institutet. Dr Kadetoff’s expertise informs the course’s approach to complex pain and long-term conditions.

Dr Lisa Palmlöf – Medical Director, Sapphire Clinics Sweden

Dr Lisa Palmlöf is a specialist in rehabilitation medicine with experience in highly specialised, team-based pain care at Danderyd Hospital Rehabilitation Medicine University Clinic. She’s also worked in neurological rehabilitation in different hospitals and has specialist education in Functional Medicine.

Dr Palmlöf contributes expertise in functional assessment and integrated rehabilitation models. She also has a Postgraduate Certificate (PGCert) in cognitive behavioural therapy (CBT).

Poland

Dr Paweł Dryżałowski – Medical Doctor and Founder, Fitokan Clinic, Poland

A graduate of the Medical University of Lublin, Dr Paweł Dryżałowski specialises in paediatric neurology. Dr Dryżałowski has authored and contributed to numerous scientific publications and textbook chapters in neurology. He lectures at national and international conferences on neurology and pain management, and is an active educator in phytocannabinoid therapy. Dr Dryżałowski’s contribution strengthens the course’s neurological and educational perspectives.

Ongoing review and updates

Medical cannabis research and regulatory frameworks continue to evolve.

To ensure the programme remains current and clinically robust:

  • Content is reviewed on a scheduled and documented basis
  • Updates are implemented in response to significant new evidence or clinical guidance
  • Version history is maintained within a formal internal governance framework
  • Feedback from healthcare professionals is incorporated where appropriate

We aim to provide education that is trustworthy, innovative, and globally adaptable – supporting clinicians to make informed, responsible decisions in practice.